Associated Papers
KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer.
Bambach NE et al.
Frontiers in Oncology, 2025
41573641 (PubMed )
Supplement: Table2.xlsx › Sheet1
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.
Aboulkassim T et al.
Cell Reports, 2023
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.
Rustad EH et al.
Blood Cancer Journal, 2015
25794135 (PubMed )
Supplement: bcj201524x1.xls › Sheet1
Select a paper to view details